Revisión literaria sobre el trasplante de células madre hematopoyéticas, opciones para mejorar la asimilación y su impacto en la supervivencia de los pacientes

Contenido principal del artículo

Laura Alejandra Lambis Loaiza

Resumen

El trasplante de células madre hematopoyéticas resulta un procedimiento muy beneficioso para el tratamiento de enfermedades hematológicas en las cuales la única posibilidad de cura es por medio de este método. Para realizar el trasplante existen varias opciones: trasplante autólogo y alogénico. Existen complicaciones que han tratado de evitarse adoptando medidas que en algunas ocasiones han resultado exitosas. El beneficio que este procedimiento representa ha hecho que sea adoptado por muchas personas y ha llevado al aumento de donantes a nivel mundial.

Detalles del artículo

Sección
Artículos de Revisión de Tema

Citas

1. Zhao X, Gao S, Wu Z, Kajigaya S, Feng X, Liu Q, Et al. Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells. Blood 2017;130(25):2762-2773. DOI: 10.1182/blood-2017-08-803353.
2. Martinez J. Anticuerpos, antígenos leucocitarios humanos y biomoduladores en los efectos adversos agudos de las trasfusiones. Gaceta médica de México 2013; 149: 81-8.
3. Solh M. Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia. World J Stem Cells 2014; 6(4):371-9. DOI: 10.4252/wjsc.v6.i4.371.
4. Henig I, Zuckerman T. Hematopoietic stem cell transplantation-50 years of evolution and future perspectives Rambam Maimonides Med J 2014;5(4):e0028. DOI: 10.5041/RMMJ.10162.
5. Esteves I, Santos FPS, Ribeiro AAF, Kondo AT, Fernandes JF, Kerbauy FR,Kerbauy L, Hamerschlak N. Survival, toxicity and length of stay after haploidentical or cord blood transplantation in a Latin American center: a cross-sectional, comparative study Blood Cancer J. 2017;7(5):e563. DOI:10.1038/bcj.2017.44.
6. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Et al. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol Medicine (Baltimore) 2018; 97(17):e0449. DOI: 10.1097/MD.0000000000010449.
7. Inagaki J, Fukano R, Noguchi M, Okamura J. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies. Int J Hematol 2017;105(5):676-685. DOI: 10.1007/s12185-017-2189-1.
8. Chen DP, Chang SW, Jaing TH, Wang WT, Hus FP, Tseng CP. Single nucleotide polymorphisms within HLA region are associated with disease relapse for patients with unrelated cord blood transplantation. PeerJ 2018;6:e5228. DOI:10.7717/peerj.5228.
9. Park BK, Kim HS, Kim S, Lee JW, Park YS, Jang PS, Et al. Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin. Blood Res 2018; 53(2):145-151. DOI: 10.5045/br.2018.53.2.145.
10. Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 2018;11(1):33. DOI: 10.1186/s13045-018-0564-x.
11. Lou X, Zhao C, Chen H. Unrelated donor umbilical cord blood transplant versus unrelated hematopoietic stem cell transplant in patients with acute leukemia: A meta-analysis and systematic review. Blood Rev 2018; 32(3):192-202. DOI:10.1016/j.blre.2017.11.003.
12. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry N Engl J Med 2014; 371(4):339-48. DOI: 10.1056/NEJMsa1311707.
13. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2017; 52(6):811-817. DOI: 10.1038/bmt.2017.34.
14. Little AM, Green A, Harvey J, Hemmatpour S, Latham K, Marsh SG, Et al. BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation. Int J Immunogenet 2016; 43(5):263-86. DOI:10.1111/iji.12282.
15. Lozano S, Altaf SY, Olavarria E. Allogeneic stem cell transplantation from unrelated donors in acute leukaemia. Curr Opin Oncol 2018; 30(6):418-424. DOI:10.1097/CCO.0000000000000485.
16. Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Brånvall E, Et al. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol 2016; 91(6):551-5. DOI: 10.1002/ajh.24342.
17. Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol 2016; 172(3):360-70. DOI: 10.1111/bjh.13802.
18. Han DM, Zheng XL, Ding L, Yan HM, Wang ZD, Xue M, Et al. Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia. Int J Hematol 2017; 106(6):820-831. DOI: 10.1007/s12185-017-2317-y.
19. Xu LP, Wu DP, Han MZ, Huang H, Liu QF, Liu DH, Et al. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. Bone Marrow Transplant 2017; 52(11):1512-1518. DOI: 10.1038/bmt.2017.59.
20. Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, Et al. Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. Bone Marrow Transplant 2017; 52(10):1390-1398. DOI: 10.1038/bmt.2017.153.
21. Medinger M, Passweg J. What the internist should know about stem cell transplant in the elderly patient. Eur J Intern Med 2018; 58:43-47.. DOI: 10.1016/j.ejim.2018.06.018.
22. Saeed H, Yalamanchi S, Liu M, Van Meter E, Gul Z, Monohan G, Et al. Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort. Hematol Oncol Stem Cell Ther 2018;11(2):90-95. DOI: 10.1016/j.hemonc.2017.12.002.
23. Gómez D, Ruiz G, Gutierrez C, Perez J. Trasplante no mieloablativo de células progenitoras hematopoyéticas. Mitos y realidades. Revista de investigación clínica 2005; 57(2):291-297
24. Qiao J, Liu L, Xia Y, Ju W, Zhao P, Jiang Y, Et al. Macrophages ameliorate bone marrow inflammatory injury and promote hematopoiesis in mice following hematopoietic stem cell transplantation. Exp Ther Med 2018; 16(2):567-572. DOI:10.3892/etm.2018.6209.
25. Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Et al. Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 2018; 379(11):1028-1041. DOI: 10.1056/NEJMoa1804714.
26. Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, Et al. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci 2017; 108(12):2445-2453. DOI: 10.1111/cas.13409.
27. Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, et al. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018; 25(1):114-120. DOI:10.1016/j.bbmt.2018.08.026.
28. Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol 2018; 93(10):1236-244. DOI: 10.1002/ajh.25231
29. Benjamin DK Jr, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002;21(3):227-34.
30. Wang Y, Chen H, Chen J, Han M, Hu J, Jiong Hu, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 2018; 438:63-75. DOI: 10.1016/j.canlet.2018.08.030.
31. Chen CT, Gau JP, Liu JH, Chiou TJ, Hsiao LT, Liu YC. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia. J Chin Med Assoc 2018; 81(2):1038-1043. DOI: 10.1016/j.jcma.2018.06.005.
32. Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014; 99(2):322-8. DOI:10.3324/haematol.2013.094193.
33. Zhang J, Chen X, Rong G, Xu T, Zhao H, Chen D, et al. Peripheral blood lymphocyte responses to cytomegalovirus seropositivity after allogeneic hematopoietic stem cell transplantation. Onco Targets Ther 2018; 11:5143-5150. DOI:10.2147/OTT.S160178.
34. Han LJ, Wang Y, Fan ZP, Huang F, Zhou J, Fu YW, Et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol 2017; 179(1):120-130. DOI: 10.1111/bjh.14854.
35. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic Cell Transplantation. N Engl J Med 2017; 377(25):2433-2444. DOI: 10.1056/NEJMoa1706640.
36. Wang J, Wang Z, Wei W, Zhang W, Zhang T, Cheng H, et al. Cord Haplo Identical Non-In vitro T-cell depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse for Refractory Acute Leukemia. Biol Blood Marrow Transplant 2018; 25(1):121-128. DOI: 10.1016/j.bbmt.2018.09.002
37. Alexander S, Fisher BT, Gaur AH, Dvorak CC, Villa Luna D, Dang H, Et al. Children’s Oncology Group Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 2018; 320(10):995-1004. DOI:10.1001/jama.2018.12512.
38. Foster JH, Cheng WS, Nguyen NY, Krance R, Martinez C. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer 2018. DOI: 10.1002/pbc.27348.
39. Kim MH, Shah S, Bottomley SS, Shah NC. Reduced toxicity allogeneic hematopoietic stem cell transplantation in congenital sideroblastic anemia. Clin Case Rep 2018; 6(9):1841-1844. DOI: 10.1002/ccr3.1667.
40. Byrne M, Savani B, Savona MR. Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. Ther Adv Hematol 2018; 9(9):251-259. DOI: 10.1177/2040620718786437
41. Arain A. Vitamin D deficiency and graft-versus-host disease in hematopoietic stem cell transplant population. Hematol Oncol Stem Cell Ther 2018. En prensa. DOI: 10.1016/j.hemonc.2018.08.001.
42. Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications. Int J Mol Sci 2018;19(9). 19(9):2663. DOI: 10.3390/ijms19092663.
43. Allen ES, Srivastava K, Hsieh MM, Fitzhugh CD, Klein HG, Tisdale JF, et al. Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematol 2017; 4(11):e553-e561. DOI: 10.1016/S2352-3026(17)30196-5.
44. Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, et al. Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2018; 24(11):2277-2284. DOI: 10.1016/j.bbmt.2018.06.024.
45. Handgretinger R, Schilbach K. The potential role of γδ T cells after allogeneic HCT for leukemia. Blood 2018; 131(10):1063-1072. DOI: 10.1182/blood-2017-08-752162.
46. Kollu V, Mott SL, Khan R, Farooq U, Jethava Y, Dilek I, et al. C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Cureus 2018; 10(7):e2945. DOI: 10.7759/cureus.2945.
47. Rocha C, López J, Orrego J, Coll Y, Karduss A, Rosenzweig S, et al. Reconstitución inmune exitosa mediante trasplante de células madre hematopoyéticas en un paciente colombiano afectado con enfermedad granulomatosa crónica. Biomédica 2016; 36:204-12. DOI: 10.7705 biomedica.v36i2.2870.
48. Medina D, Martínez L, Dávalos D, Manzi E, Rosales M. Trasplante autólogo de células madre hematopoyéticas en pacientes con diagnóstico de neuroblastoma de alto riesgo en la Fundación Valle del Lili, Cali- Colombia. Rev. Colomb. Cacerol 2017; 21(1):3-11. DOI: 10.1016jrcca.2017.02.080.
49. Trounson A, McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell 2015; 17(1):11-22. DOI: 10.1016/j.stem.2015.06.007.
50. Lapostolle V, Chevaleyre J, Duchez P, Rodriguez L, Vlaski-Lafarge M, Sandvig I, et al. Repopulating hematopoietic stem cells from steady-state blood before and after ex vivo culture are enriched in CD34+CD133+CXCR4 low fraction. Haematologica 2018; 103(10):1604-1615. DOI:10.3324/haematol.2017.183962.
51. Stern L, McGuire H, Avdic S, Rizzetto S, Fazekas de St Groth B, Luciani F, Et al. Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation. Front Immunol 2018; 9:1672.DOI: 10.3389/fimmu.2018.01672.
52. Farhadfar N, Hogan WJ. Overview of the progress on haploidentical hematopoietic transplantation. World J Transplant 2016; 6(4):665-674. DOI: 10.5500/wjt.v6.i4.665.
53. Ehl S, Astigarraga I, Von Bahr Greenwood T, Hines M, Horne A, Ishii E, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract 2018; 6(5):1508-1517. DOI: 10.1016/j.jaip.2018.05.031.
54. Ruiz MA, Kaiser RL Jr, de Quadros LG, Piron-Ruiz L, Peña-Arciniegas T, Faria MAG, et al. Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease. BMC Res Notes 2017; 10(1):495. DOI: 10.1186/s13104-017-2824-1.
55. Bertaina A, Andreani M. Major Histocompatibility Complex and Hematopoietic Stem Cell Transplantation: Beyond the Classical HLA Polymorphism. Int J Mol Sci 2018;19(2). 19(2):621. DOI: 10.3390/ijms19020621.
56. Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, et al. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant 2018; 53(6):756-763. DOI: 10.1038/s41409-018-0126-4.
57. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 2017; 102(2):391-400. DOI: 10.3324/haematol.2016.144139